Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. [electronic resource]
Producer: 20130404Description: 740-8 p. digitalISSN:- 1537-6613
- Adult
- Aged
- Anti-HIV Agents -- administration & dosage
- Antiretroviral Therapy, Highly Active -- methods
- Drug Resistance, Viral
- Female
- HIV Infections -- drug therapy
- HIV-1 -- drug effects
- Heterocyclic Compounds, 3-Ring -- administration & dosage
- Humans
- Male
- Middle Aged
- Oxazines
- Pilot Projects
- Piperazines
- Plasma -- virology
- Pyridones
- Pyrrolidinones -- pharmacology
- RNA, Viral -- blood
- Raltegravir Potassium
- Treatment Outcome
- Viral Load
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.